immunocore-logo-2018
Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2021 09:05 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology...
immunocore-logo-2018
Immunocore to present at upcoming investor conferences
May 27, 2021 16:30 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 27 May 2021) Immunocore (Nasdaq: IMCR), a late-stage...
immunocore-logo-2018
Immunocore Reports First Quarter 2021 Financial Results
May 12, 2021 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports First Quarter 2021 Financial Results Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) is expected to be completed in...
Immunocore1.png
Immunocore announces key appointments to management and Board
February 16, 2021 07:00 ET | Immunocore Limited
PRESS RELEASE Immunocore announces key appointments to management and Board Ralph Torbay appointed Head of Commercial to spearhead the launch of tebentafusp Dr. Roy S. Herbst appointed as a...
Immunocore1.png
Immunocore Announces Pricing of Upsized Initial Public Offering
February 04, 2021 22:07 ET | Immunocore Limited
PRESS RELEASE Immunocore Announces Pricing of Upsized Initial Public Offering OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 4 February 2021 – Immunocore Holdings plc...
Immunocore1.png
Immunocore announces closing of $75.0 Million Series C round
January 11, 2021 07:00 ET | Immunocore Limited
PRESS RELEASE Immunocore announces closing of $75.0 Million Series C round Funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma ...
Immunocore1.png
Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020
December 03, 2020 06:01 ET | Immunocore Limited
PRESS RELEASE Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3...
Immunocore1.png
Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B
August 27, 2020 07:00 ET | Immunocore Limited
PRESS RELEASE Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B New preclinical...
Immunocore1.png
Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B
August 27, 2020 02:00 ET | Immunocore Limited
PRESS RELEASE Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B New preclinical...
Immunocore1.png
Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy
May 06, 2020 07:00 ET | Immunocore Limited
PRESS RELEASE Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy (OXFORD, England & CONSHOHOCKEN, Pa. & ROCKVILLE, Md., 6 May 2020) Immunocore, a...